Best Practices for the Medical Oncology Boards

News
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

The medical oncology board examinations are a pivotal time in a clinician's career. However, preparing for and taking this examination comes as a crucial moment when residents/fellows begin their transition to attending.

Although in theory the process of taking an examination and then beginning a new job sounds simple, it is quite complex. The hematology/oncology boards require rigorous preparation. The examination is followed by the new attending position, where clinicians, for the first time, are on their own, making treatment decisions and leading a team.

ONCOLOGY® spoke with leading clinicians as well as those who are just beginning their careers about this time and how they handled studying while experiencing personal and professional changes.

Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, focused on:

  • His transition from fellow to attending (0:58)
  • Where students should focus their efforts on studying (2:11)
  • Advice he would give to those currently studying (2:47)

Nicholas James Hornstein, MD, PhD, assistant professor at Northwell Health Cancer Institute, discussed:

  • Studying for the boards while balancing a new career (3:18)
  • Specific study areas the examination focuses on (5:43)

Marc J. Braunstein, MD, associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine, fellowship program director in hematology/oncology at NYU Langone Health—Long Island, and codirector of the Hematology-Oncology System at NYU Grossman Long Island School of Medicine, highlighted:

  • How to prepare fellows for the career transition (7:11)
  • Advice he gives about this transition (8:17)

Nerea M. Lopetegui-Lia, MD, assistant professor in the College of Medicine at The Ohio State University Comprehensive Cancer Center–The James, spoke about:

  • Best review practices for the examination (9:01)
  • Advice she would give to those studying (10:15)

MinhTri Nguyen, MD, a medical oncologist with Stanford Medicine, focused on:

  • As a leadership coach, helping prepare residents/fellows for the career transition (11:36)
  • Advice he would give to those studying (14:34)
Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Discussing Early ctDNA Detection Through MCED Blood Tests

Tim Cortese
July 31st 2025
Article

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

EU approval of the agent is based on phase 2b ReNeu trial results, which met its primary end point of confirmed objective response rate in NF1-PN.

Mirdametinib Earns Conditional European Approval in Adult/Pediatric NF1-PN

Roman Fabbricatore
July 21st 2025
Article

EU approval of the agent is based on results from the phase 2b ReNeu trial, which met its primary end point of confirmed objective response rate in NF1-PN.